

citizens electronically and via hard copy. These comments were considered and evaluated in preparing the Final Programmatic EIS. Within the Final Programmatic EIS, BOEM presents the baseline conditions, analyzes reasonably foreseeable impacts to marine resources and, where applicable, identifies and analyzes potential mitigation and monitoring measures to avoid, reduce, or minimize potential impacts. It also establishes a framework for future environmental analyses of site-specific activities before BOEM authorizes any individual permits for those activities.

The Final Programmatic EIS identifies BOEM's Preferred Alternative which provides programmatic-level mitigation, monitoring and reporting requirements meant to reduce the potential for adverse impacts to Mid- and South Atlantic resources from reasonably foreseeable G&G activities across all three BOEM program areas. It also includes an adaptive management strategy that, through site-specific NEPA analysis, will incorporate new information, establish additional measures and/or adjust existing measures based on monitoring results.

Please note that the Final Programmatic EIS does not address the potential environmental effects of oil and gas leasing, development, or production in the Mid- and South Atlantic. BOEM has not proposed oil and gas leasing, development or production in the Mid- and South Atlantic at this time, and additional environmental analyses would be necessary prior to proceeding with any such activities.

Final Programmatic EIS Availability: In keeping with the Department of the Interior's mission to protect natural resources and to limit costs while ensuring availability of the document to the public, BOEM will primarily distribute digital copies of the Final Programmatic EIS on compact discs. However, BOEM has printed and will be distributing a limited number of paper copies. If you require a paper copy, BOEM will provide one upon request if copies are still available.

1. You may request a hard copy or compact disc of the Final Programmatic EIS from the Bureau of Ocean Energy Management, Gulf of Mexico OCS Region, Public Information Office (GM 335A), 1201 Elmwood Park Boulevard, Room 250, New Orleans, Louisiana 70123-2394 (1-800-200-GULF (4853)).

2. You may download or view the Final Programmatic EIS on BOEM's project Web site at <http://boem.gov/and-Gas-Energy-Program//.aspx> or on BOEM's EIS Web site at <http://www.boem.gov/nepaprocess/>.

Several libraries along the Atlantic Coast have been sent copies of the Final Programmatic EIS. To find out which libraries have copies of the Final Programmatic EIS for review, you may contact BOEM's Public Information Office or visit BOEM's Internet Web site at <http://www.boem.gov/nepaprocess/>.

Public Disclosure of Names and Addresses: Before including your address, telephone number, email address, or other personal identifying information in your comment, be advised that your entire comment, including your personal identifying information, may be made publicly available at any time. While you can ask us in your comment to withhold from public review your personal identifying information, we cannot guarantee that we will be able to do so.

Authority: This NOA is published pursuant to the regulations (40 CFR part 1503) implementing the provisions of NEPA, as amended (42 U.S.C. 4321 *et seq.*).

Dated: January 10, 2014.

Tommy P. Beaudreau,
Director, Bureau of Ocean Energy
Management.

[FR Doc. 2014-05046 Filed 3-6-14; 8:45 am]

BILLING CODE 4310-MR-P

INTERNATIONAL TRADE COMMISSION

Notice of Receipt of Complaint; Solicitation of Comments Relating to the Public Interest

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

SUMMARY: Notice is hereby given that the U.S. International Trade Commission has received a complaint entitled *Certain Hemostatic Products and Components Thereof; DN 3003*; the Commission is soliciting comments on any public interest issues raised by the complaint or complainant's filing under section 210.8(b) of the Commission's Rules of Practice and Procedure (19 CFR 210.8(b)).

FOR FURTHER INFORMATION CONTACT: Lisa R. Barton, Acting Secretary to the Commission, U.S. International Trade Commission, 500 E Street SW., Washington, DC 20436, telephone (202) 205-2000. The public version of the complaint can be accessed on the Commission's Electronic Document Information System (EDIS) at *EDIS*,¹ and will be available for inspection during official business hours (8:45 a.m. to 5:15

p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street SW., Washington, DC 20436, telephone (202) 205-2000.

General information concerning the Commission may also be obtained by accessing its Internet server at United States International Trade Commission (USITC) at *USITC*.² The public record for this investigation may be viewed on the Commission's Electronic Document Information System (EDIS) at *EDIS*.³ Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on (202) 205-1810.

SUPPLEMENTARY INFORMATION: The Commission has received a complaint and a submission pursuant to section 210.8(b) of the Commission's Rules of Practice and Procedure filed behalf of Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA, on February 28, 2014. The complaint alleges violations of section 337 of the Tariff Act of 1930 (19 U.S.C. 1337) in the importation into the United States, the sale for importation, and the sale within the United States after importation of certain hemostatic products and components thereof. The complaint name as respondents Johnson and Johnson Inc. Brunswick, NJ, Ethicon, Inc., Somerville, NJ, Ferrosan Medical Devices A/S, Denmark, Packaging Coordinators, Inc., Philadelphia, PA. The complainant requests that the Commission issue a permanent limited exclusion order, permanent cease and desist orders, and impose a bond during any Presidential Review period.

Proposed respondents, other interested parties, and members of the public are invited to file comments, not to exceed five (5) pages in length, inclusive of attachments, on any public interest issues raised by the complaint or section 210.8(b) filing. Comments should address whether issuance of the relief specifically requested by the complainant in this investigation would affect the public health and welfare in the United States, competitive conditions in the United States economy, the production of like or directly competitive articles in the United States, or United States consumers.

In particular, the Commission is interested in comments that:

(i) Explain how the articles potentially subject to the requested

² United States International Trade Commission (USITC): <http://edis.usitc.gov>.

³ Electronic Document Information System (EDIS): <http://edis.usitc.gov>.

¹ Electronic Document Information System (EDIS): <http://edis.usitc.gov>.

remedial orders are used in the United States;

(ii) identify any public health, safety, or welfare concerns in the United States relating to the requested remedial orders;

(iii) identify like or directly competitive articles that complainant, its licensees, or third parties make in the United States which could replace the subject articles if they were to be excluded;

(iv) indicate whether complainant, complainant's licensees, and/or third party suppliers have the capacity to replace the volume of articles potentially subject to the requested exclusion order and/or a cease and desist order within a commercially reasonable time; and

(v) explain how the requested remedial orders would impact United States consumers.

Written submissions must be filed no later than by close of business, eight calendar days after the date of publication of this notice in the **Federal Register**. There will be further opportunities for comment on the public interest after the issuance of any final initial determination in this investigation.

Persons filing written submissions must file the original document electronically on or before the deadlines stated above and submit 8 true paper copies to the Office of the Secretary by noon the next day pursuant to section 210.4(f) of the Commission's Rules of Practice and Procedure (19 CFR 210.4(f)). Submissions should refer to the docket number ("Docket No. 3003") in a prominent place on the cover page and/or the first page. (See Handbook for Electronic Filing Procedures, *Electronic Filing Procedures*⁴). Persons with questions regarding filing should contact the Secretary (202–205–2000).

Any person desiring to submit a document to the Commission in confidence must request confidential treatment. All such requests should be directed to the Secretary to the Commission and must include a full statement of the reasons why the Commission should grant such treatment. See 19 CFR 201.6. Documents for which confidential treatment by the Commission is properly sought will be treated accordingly. All nonconfidential written submissions will be available for public inspection at the Office of the Secretary and on *EDIS*.⁵

This action is taken under the authority of section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and of sections 201.10 and 210.8(c) of the Commission's Rules of Practice and Procedure (19 CFR 201.10, 210.8(c)).

By order of the Commission.

Issued: February 28, 2014.

William R. Bishop,

Supervisory Hearings and Information Officer.

[FR Doc. 2014–04945 Filed 3–6–14; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[DEA #390P]

Controlled Substances: 2014 Proposed Aggregate Production Quota for Four Temporarily Controlled Synthetic Cannabinoids

AGENCY: Drug Enforcement Administration (DEA), Department of Justice.

ACTION: Notice of a proposed 2014 aggregate production quota for four synthetic cannabinoids.

SUMMARY: Four synthetic cannabinoids: quinolin-8-yl 1-pentyl-1*H*-indole-3-carboxylate (PB-22; QUPIC); quinolin-8-yl 1-(5-fluoropentyl)-1*H*-indole-3-carboxylate (5-fluoro-PB-22; 5F-PB-22); *N*-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1*H*-indazole-3-carboxamide (AB-FUBINACA); and *N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1*H*-indazole-3-carboxamide (ADB-PINACA) were temporarily placed in schedule I of the Controlled Substances Act (CSA) by a final order published by the DEA on February 10, 2014 (79 FR 7577). This means that any manufacturer that wishes to manufacture PB-22, 5F-PB-22, AB-FUBINACA, or ADB-PINACA after February 10, 2014, must be registered with the DEA and have obtained a manufacturing quota for PB-22, 5F-PB-22, AB-FUBINACA, or ADB-PINACA pursuant to 21 CFR part 1303.

The DEA cannot issue individual manufacturing quotas for PB-22, 5F-PB-22, AB-FUBINACA, or ADB-PINACA unless and until it establishes an aggregate production quota. Therefore, this notice proposes a 2014 aggregate production quota for PB-22, 5F-PB-22, AB-FUBINACA, and ADB-PINACA.

DATES: Comments or objections should be received on or before April 7, 2014.

ADDRESSES: To ensure proper handling of comments, please reference "Docket

No. DEA–390P" on all electronic and written correspondence. The DEA encourages that all comments be submitted electronically through www.regulations.gov using the electronic comment form provided on that site. An electronic copy of this document is also available at www.regulations.gov for easy reference. Paper comments that duplicate the electronic submission are not necessary as all comments submitted to www.regulations.gov will be posted for public review and are part of the official docket record. Written comments submitted via regular or express mail should be sent to the Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODW, 8701 Morrisette Drive, Springfield, Virginia 22152.

FOR FURTHER INFORMATION CONTACT:

Ruth A. Carter, Office of Diversion Control, Drug Enforcement Administration; Mailing Address: 8701 Morrisette Drive, Springfield, Virginia 22152, Telephone: (202) 598–6812.

SUPPLEMENTARY INFORMATION:

Posting of Public Comments

The Freedom of Information Act applies to all comments received. All comments received are considered part of the public record and made available for public inspection online at www.regulations.gov and in the DEA's public docket. Such information includes personal identifying information (such as your name, address, etc.) voluntarily submitted by the commenter.

If you want to submit personal identifying information (such as your name, address, etc.) as part of your comment, but do not want it to be posted online or made available in the public docket, you must include the phrase "PERSONAL IDENTIFYING INFORMATION" in the first paragraph of your comment. You must also place all the personal identifying information you do not want posted online or made available in the public docket in the first paragraph of your comment and identify what information you want redacted.

If you want to submit confidential business information as part of your comment, but do not want it to be posted online or made available in the public docket, you must include the phrase "CONFIDENTIAL BUSINESS INFORMATION" in the first paragraph of your comment. You must also prominently identify confidential business information to be redacted within the comment. If a comment has so much confidential business information that it cannot be effectively

⁴ Handbook for Electronic Filing Procedures: http://www.usitc.gov/secretary/fed_reg_notices/rules/handbook_on_electronic_filing.pdf

⁵ Electronic Document Information System (EDIS): <http://edis.usitc.gov>.